Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

SerenOx Africa aims to address diagnostic gaps for common blood disorders through a testing facility for key underserved patient populations in Tanzania. This facility will also aim to provide early cancer detection for high-risk patients.

Portrait of Prof Anna S.

Commenting on the launch, Professor Anna Schuh, Director of Molecular Diagnostics in the Department of Oncology, said: ‘A precise diagnosis is essential in delivering the right treatment to the right patient and at the right time, however 47% of the global population has little to no access to diagnostics. When it comes to common and potentially curable diseases like some types of anaemia or cancers, a late diagnosis or a misdiagnosis majorly contributes to these diseases’ poor outcomes.’

In sub-Saharan Africa, many diseases that can be easily cured or well controlled with affordable therapies are currently not being diagnosed. For early-stage cancer – adds Schuh - over 90% of patients can be cured in-country with treatment that costs a fraction of those for late-stage cancer.

Read the full story on Oxford Cancer website

Similar stories

Novel inhaled TB vaccine

The Jenner Institute is conducting a new study, using BCG, the current licensed vaccine against tuberculosis. In this study, they will give BCG a second time to people who have already had BCG once before, and will compare whether giving it by inhalation is better at protecting people against tuberculosis than giving it into the skin